Incidence and survival of childhood central nervous system tumors in Denmark, 1997-2019.
central nervous system tumor
childhood cancer
childhood cancer survivors
incidence
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
01
10
2021
received:
24
08
2021
accepted:
04
11
2021
pubmed:
21
11
2021
medline:
22
3
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Incidence rates in Denmark of central nervous system (CNS) tumors remain among the highest in the world. Survival rates, however, have improved in the past decades in high-income countries. We analyzed incidence and survival of childhood CNS tumors in Denmark diagnosed from 1997 to 2019 based on data from the Danish Childhood Cancer Registry and information on histological types, tumor localization, and treatment from medical records. From 1997 to 2019, 949 children<15 years were diagnosed with a CNS tumor. Age-standardized incidence was 42.1 (95% CI, 39.4-44.6) per million person-years and stable during this period. Age-specific incidence for children aged 0-4 years was 47.7 per million. More than one-third (n = 374, 39.4%) were treated with surgery alone. Overall survival rates 5 and 10 years after diagnosis were 77.6% (95% CI, 74.7-80.2) and 74.7% (95% CI, 71.7-77.5). Five-year overall survival improved from 73.0% (95% CI, 68.9-76.7) in 1997-2008 to 83.2% (95% CI, 79.2-86.4) in 2009-2019 (p-value < 0.0001) in children aged 0-4 years (p = 0.0006). Incidence rates are stable but remain among the highest in the world. Despite improved survival rates in recent years in younger children, some subtypes still have a poor prognosis.
Sections du résumé
BACKGROUND
Incidence rates in Denmark of central nervous system (CNS) tumors remain among the highest in the world. Survival rates, however, have improved in the past decades in high-income countries.
METHODS
We analyzed incidence and survival of childhood CNS tumors in Denmark diagnosed from 1997 to 2019 based on data from the Danish Childhood Cancer Registry and information on histological types, tumor localization, and treatment from medical records.
RESULTS
From 1997 to 2019, 949 children<15 years were diagnosed with a CNS tumor. Age-standardized incidence was 42.1 (95% CI, 39.4-44.6) per million person-years and stable during this period. Age-specific incidence for children aged 0-4 years was 47.7 per million. More than one-third (n = 374, 39.4%) were treated with surgery alone. Overall survival rates 5 and 10 years after diagnosis were 77.6% (95% CI, 74.7-80.2) and 74.7% (95% CI, 71.7-77.5). Five-year overall survival improved from 73.0% (95% CI, 68.9-76.7) in 1997-2008 to 83.2% (95% CI, 79.2-86.4) in 2009-2019 (p-value < 0.0001) in children aged 0-4 years (p = 0.0006).
CONCLUSION
Incidence rates are stable but remain among the highest in the world. Despite improved survival rates in recent years in younger children, some subtypes still have a poor prognosis.
Identifiants
pubmed: 34800006
doi: 10.1002/cam4.4429
pmc: PMC8704152
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-256Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Clin Epidemiol. 2016 Oct 25;8:461-464
pubmed: 27822085
J Glob Oncol. 2019 Oct;5:1-25
pubmed: 31682549
Lancet Child Adolesc Health. 2018 May;2(5):321-337
pubmed: 29732397
Am J Surg Pathol. 1998 Sep;22(9):1083-92
pubmed: 9737241
Eur J Cancer. 2017 Sep;82:137-148
pubmed: 28689091
Curr Opin Pediatr. 2021 Feb 1;33(1):33-39
pubmed: 33337604
Br J Cancer. 2006 Aug 7;95(3):416-22
pubmed: 16868540
Acta Oncol. 2020 May;59(5):588-595
pubmed: 32048526
Pediatr Blood Cancer. 2011 Jan;56(1):65-9
pubmed: 21108441
BMC Cancer. 2019 Feb 11;19(1):139
pubmed: 30744596
Neuro Oncol. 2014 Jul;16(7):975-83
pubmed: 24470548
Cancer. 2008 Feb 1;112(3):461-72
pubmed: 18072274
AJR Am J Roentgenol. 1986 Sep;147(3):453-5
pubmed: 3488645
Acta Paediatr. 2009 Oct;98(10):1620-7
pubmed: 19594464
Eur J Cancer. 2001 Apr;37(6):711-21
pubmed: 11311645
Front Pediatr. 2018 Apr 20;6:114
pubmed: 29732366
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Cancer Epidemiol. 2020 Aug;67:101768
pubmed: 32593162
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Cancer Med. 2022 Jan;11(1):245-256
pubmed: 34800006
Dtsch Arztebl Int. 2011 Jun;108(22):390-7
pubmed: 21712972
Br J Cancer. 2010 Feb 2;102(3):620-6
pubmed: 20051948
J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77
pubmed: 9731733
Lancet Oncol. 2018 Sep;19(9):1159-1169
pubmed: 30098952
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Neuro Oncol. 2017 May 1;19(5):699-709
pubmed: 28453743
Brain Pathol. 2020 Sep;30(5):863-866
pubmed: 32502305
Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa012
pubmed: 32161911
Cancer. 2018 Nov 1;124(21):4168-4180
pubmed: 30255939
J Natl Cancer Inst. 1998 Sep 2;90(17):1249-51
pubmed: 9731726
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931